Effect of Pramipexole combined with Levodopa and Benserazide Hy-drochloride Tablets in the treatment of Parkinson's disease
Objective To analyze and study the value of Pramipexole combined with Levodopa and Benserazide Hydrochloride Tablets in the treatment of Parkinson's disease.Methods Fifty patients diagnosed with Parkinson's disease for the first time in the Department of Neurology,Macheng City People's Hospital,Hubei Province from January 2020 to January 2023 were selected as the observation subjects of this study.All patients were divided into two groups using random number table method,with 25 cases in each group.The observation group was treated with Pramipexole combined with Levodopa and Benserazide Hydrochloride Tablets,while the control group was only treated with Levodopa and Benserazide Hydrochloride Tablets.Both groups were treated for 3 months.Clinical efficacy,movement symptoms,quality of life,homocysteine(Hey),amyloid-[3 protein 1-42(Aβ1-42)levels,and drug safety were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P＜0.05).There were no statistically significant difference in Parkinson's disease rating scale(UPDRS)Ⅱ,UPDRS Ⅲ,UPDRS Ⅱ+Ⅲscore between the two groups before treatment(P＞0.05).The UPDRS Ⅱ,UPDRSⅢ and UPDRS Ⅱ+Ⅲ scores of the observation group were lower than those of the control group after treatment,and the differences were statistically significant(P＜0.05).There was no statistical significance in the score of 39 item Parkinson's disease questionnaire(PDQ-39)before treatment between the two groups(P＞0.05).The PDQ-39 score of observation group was lower than that of control group after treatment,and the difference was statistically significant(P＜0.05).There was no significant difference in serum Hey and Aβ1-42 between the two groups before treatment(P＞0.05).After treatment,the serum Hey level in the observation group was lower than that in the control group,and the level of Aβ1-42 was higher than that in the control group,the differences were statistically significant(P＜0.05).There was no significant difference in the total adverse reaction rate between the two groups(P＞0.05).Conclusion Pramipexole+Levodopa and Benserazide Hydrochloride Tablets have significantly better value than Levodopa and Benserazide Hydrochloride Tablets alone in the treatment of Parkinson's disease.At the same time,it can significantly improve patients'motor symptoms,improve their quality of life and Aβ1-42 levels,and reduce Hey levels,and it is highly safe and worthy of widespread clinical application.
Parkinson's diseasePramipexoleLevodopa and Benserazide Hydrochloride TabletsQuality of Life
万方数据
维普
